ACD856

ACD856 is a novel small molecule and first-in-class positive allosteric modulator of tropomyosin receptor kinase (Trk) receptors, specifically enhancing the signaling of neurotrophins such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). By potentiating TrkA and TrkB receptor activity, ACD856 increases neurotrophin signaling pathways that are critical for neuronal survival, synaptic plasticity, mitochondrial function, and cognitive processes. The drug has demonstrated pro-cognitive, anti-depressant-like effects in animal models and shows potential for both symptomatic relief and disease-modifying effects in neurodegenerative diseases. Developed by AlzeCure Pharma under its NeuroRestore platform, ACD856 is being advanced primarily for Alzheimer's disease but also considered for other conditions involving cognitive impairment such as Parkinson's disease and depression. Preclinical studies indicate additional benefits including enhanced neuronal communication, increased protein levels important for synaptic function, anti-inflammatory properties, neuroprotection against cell death, improved mitochondrial function, and regenerative effects[1][2][3][6][8].

Other names

tropomyosin receptor kinase B positive allosteric modulatorTrkB positive allosteric modulatorTrkB PAMTrkA/B positive allosteric modulator